Compare Biogen Inc (BIIB) vs Dover Corp (DOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Dover Corp — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Dover Corp trades at $216.11 (market cap $28.84B). The key difference: Biogen Inc and Dover Corp are close in size by market cap, and Dover Corp pays a 0.97% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | DOV | |
|---|---|---|
Market Cap | $28.34B | $28.84B |
Sector | Health | Industrials |
52-Week High | $216.63 | $233.31 |
52-Week Low | $122.68 | $161.16 |
Enterprise Value | $30.62B | $30.49B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Dover Corporation (DOV) trades at $214.27, down 0.49% on the day, with a bearish technical signal and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $2.72. Financials show solid profitability with a 13.3% net income margin and 15.06% ROE, though cash flow turned negative in 2025. Recent news highlights product launches in fueling solutions and data center technologies, indicating ongoing innovation.
The outlook is mixed: strong analyst consensus (64% buy ratings) and a $250.67 price target suggest upside, but bearish technicals and negative net cash flow pose near-term risks. Investors should weigh robust fundamentals against market volatility and execution challenges in a competitive industrial sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
